NO20072576L - CTLA-4 antistoff og aromataseinhibitor eller kombinasjonsbehandling for brystkreft - Google Patents

CTLA-4 antistoff og aromataseinhibitor eller kombinasjonsbehandling for brystkreft

Info

Publication number
NO20072576L
NO20072576L NO20072576A NO20072576A NO20072576L NO 20072576 L NO20072576 L NO 20072576L NO 20072576 A NO20072576 A NO 20072576A NO 20072576 A NO20072576 A NO 20072576A NO 20072576 L NO20072576 L NO 20072576L
Authority
NO
Norway
Prior art keywords
breast cancer
antibody
aromatase inhibitor
ctla
combination therapy
Prior art date
Application number
NO20072576A
Other languages
English (en)
Inventor
Jesus Gomez-Navarro
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20072576L publication Critical patent/NO20072576L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen vedrører administrering av et anti-CTLA4-antistoff, spesielt humane antistoffer mot humant CTLA4, slik som de som har aminosyresekvenser til antistoffer 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9. 1.1 og I ODI (MDX-010), i kombinasjon med en aromatasehemmer, for behandlingen av brystcancer. Mer bestemt vedrører oppfinnelsen administrering av et anti-CTLA4antistoff og eksemestan for behandling av brystcancer.
NO20072576A 2004-11-04 2007-05-21 CTLA-4 antistoff og aromataseinhibitor eller kombinasjonsbehandling for brystkreft NO20072576L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62485604P 2004-11-04 2004-11-04
PCT/IB2005/003307 WO2006048749A1 (en) 2004-11-04 2005-10-24 Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer

Publications (1)

Publication Number Publication Date
NO20072576L true NO20072576L (no) 2007-08-03

Family

ID=35825412

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072576A NO20072576L (no) 2004-11-04 2007-05-21 CTLA-4 antistoff og aromataseinhibitor eller kombinasjonsbehandling for brystkreft

Country Status (15)

Country Link
EP (1) EP1819735A1 (no)
JP (1) JP2008518902A (no)
KR (1) KR20070067702A (no)
CN (1) CN101052655A (no)
AR (1) AR053651A1 (no)
AU (1) AU2005300315A1 (no)
BR (1) BRPI0515735A2 (no)
CA (1) CA2586844A1 (no)
IL (1) IL182244A0 (no)
MX (1) MX2007003804A (no)
NO (1) NO20072576L (no)
RU (1) RU2007114111A (no)
TW (1) TW200621804A (no)
WO (1) WO2006048749A1 (no)
ZA (1) ZA200702577B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937251A2 (en) * 2005-04-25 2008-07-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
KR20080030656A (ko) * 2005-07-07 2008-04-04 콜레이 파마시티컬 그룹, 인코포레이티드 암 치료를 위한 항-ＣＴＬＡ-4 항체 및 ＣｐＧ-모티프-함유합성 올리고데옥시뉴클레오티드의 조합 요법
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007113648A2 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
JP2011509299A (ja) 2008-01-08 2011-03-24 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患治療のための、抗ｃｔｌａ−４抗体とチューブリン調節剤との組み合わせ
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
CN102227503B (zh) 2008-09-26 2015-10-21 托卡根公司 重组载体
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
NO2344540T3 (no) 2008-10-02 2018-04-28
PT2769737T (pt) * 2009-07-20 2017-06-29 Bristol Myers Squibb Co Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas
CA2828940C (en) 2011-03-10 2024-04-16 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
EP3431142B1 (en) 2011-08-30 2020-06-17 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
IL301603A (en) * 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
RU2737765C2 (ru) 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
CN103768596B (zh) * 2012-10-17 2016-06-22 苏州丁孚靶点生物技术有限公司 用于肿瘤治疗的组合产品、其用途及相关方法
ES2786051T3 (es) 2012-10-25 2020-10-08 Tocagen Inc Vector retroviral con casete de mini-promotor
CA2902433A1 (en) 2013-03-01 2014-09-04 Astex Pharmaceuticals, Inc. Drug combinations
CA2926853C (en) * 2013-10-18 2022-04-26 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
JP2018526007A (ja) 2015-09-04 2018-09-13 トカジェン インコーポレーテッド ２ａペプチドを含む組換えベクター
CN106883298B (zh) * 2015-12-16 2021-12-17 上海康岱生物医药技术股份有限公司 双特异性偶联抗体及其制法和用途
US10612005B2 (en) 2016-01-08 2020-04-07 Replimune Limited Modified oncolytic virus
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018037595A1 (ja) * 2016-08-26 2018-03-01 哲治 奥野 微小血管血流低減剤およびその利用
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
PT3589661T (pt) 2017-03-02 2024-01-29 Genentech Inc Tratamento com adjuvante de cancro da mama positivo para her2
WO2018167780A1 (en) * 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
RU2020108580A (ru) 2017-08-03 2021-09-03 Оцука Фармасьютикал Ко., Лтд. Лекарственное соединение и способы его очистки
EP4110347A4 (en) * 2020-02-27 2024-05-29 University of Washington COMPOSITION AND METHOD FOR PREPARING A LONG-ACTING INJECTABLE SUSPENSION CONTAINING MULTIPLE ANTI-CANCER DRUGS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies

Also Published As

Publication number Publication date
ZA200702577B (en) 2008-07-30
CA2586844A1 (en) 2006-05-11
BRPI0515735A2 (pt) 2011-10-11
WO2006048749A1 (en) 2006-05-11
KR20070067702A (ko) 2007-06-28
EP1819735A1 (en) 2007-08-22
JP2008518902A (ja) 2008-06-05
AU2005300315A1 (en) 2006-05-11
MX2007003804A (es) 2007-04-23
TW200621804A (en) 2006-07-01
CN101052655A (zh) 2007-10-10
RU2007114111A (ru) 2008-12-10
IL182244A0 (en) 2007-09-20
AR053651A1 (es) 2007-05-16

Similar Documents

Publication Publication Date Title
NO20072576L (no) CTLA-4 antistoff og aromataseinhibitor eller kombinasjonsbehandling for brystkreft
WO2007113648A3 (en) Ctla4 antibody combination therapy
NO20056236L (no) Behandling med anti-VEGF-antistoffer
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
TW200801042A (en) Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
WO2018183888A3 (en) Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
NO20054769L (no) Substituerte fenylalkansyrer
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
MX2011006685A (es) Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
NO20055832L (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
DK1468014T3 (da) Sammensætninger og fremgangsmåder til WT1-specifik immunterapi
CY1117655T1 (el) Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων
NO20054958L (no) Substitulerte aminokarboksylsyrer
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
EA201000424A1 (ru) Антитела к il-23
CY1116728T1 (el) Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
NO20070091L (no) Sukkerbelegg og fremgangsmate for dette
NO341574B1 (no) Forbindelse, farmasøytisk sammensetning og sett for behandling av cancer eller i en avbildningsmetode.
NO20062876L (no) Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
EP4596042A3 (en) Methods for treating diabetes, hepatitis, and/or inflammatory liver disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application